Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. Photo via uh.edu

A Houston philanthropist made a $2 million gift to the University of Houston to advance health care business innovation

Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. The Elaine W. Finger Endowed Chair in Health Care Business Innovation is a joint appointment in the C.T. Bauer College of Business and the Tilman J. Fertitta Family College of Medicine. The project will aim to catalyze innovative advancements to help the university into a leading hub for innovative solutions.

The endowment was made through the Bauer Foundation, and will be matched dollar-for-dollar via UH’s Aspire Fund. The Aspire Fund is a grant program created by the gift of an anonymous donor that matches all eligible gifts up to $50 million — for a total of $100 million — and is aimed to assist in education, health care innovation research, and industry outreach.

“An investment in health care business innovation is far more than a gift, it is a visionary commitment to the future of healthcare in Houston and beyond,” Diane Z. Chase, UH senior vice president for academic affairs and provost, says in a news release. “The establishment of this Chair is a testament to our shared dedication to developing solutions that will shape the health care landscape for generations to come.”

Bauer College launched the Healthcare Business Institute, or HBI, this summer to address research and innovative solutions for quality, cost and access concerns. HBI also works to connect students, faculty and researchers from Bauer, the Fertitta Family College of Medicine and the highly ranked health law program at the UH Law Center, and other UH programs.

UH will search for a new chair that according to the university, “will be considered a thought leader in health care innovation" and who is of high national prominence and able to elevate the stature of the University of Houston by bringing a record of achievements recognized by membership in the National Academy of Science, National Academy of Medicine or another national academy related to the field of study.

Ravi Aron, research director and professor of health care strategy, currently leads HBI.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.